Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia
Chimeric antigen receptor T (CAR-T) cell therapy is a novel therapeutic modality for acute lymphoblastic leukemia (ALL) with robust outcomes in patients with refractory or relapsed disease. At the same time, CAR-T cell therapy is associated with unique and potentially fatal toxicities, such as cytok...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Elsevier
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/47a011b41a24447fbfbe666a71b1e194 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:47a011b41a24447fbfbe666a71b1e194 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:47a011b41a24447fbfbe666a71b1e1942021-11-18T04:50:57ZAssociação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia2531-137910.1016/j.htct.2021.09.002https://doaj.org/article/47a011b41a24447fbfbe666a71b1e1942021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S253113792100136Xhttps://doaj.org/toc/2531-1379Chimeric antigen receptor T (CAR-T) cell therapy is a novel therapeutic modality for acute lymphoblastic leukemia (ALL) with robust outcomes in patients with refractory or relapsed disease. At the same time, CAR-T cell therapy is associated with unique and potentially fatal toxicities, such as cytokine release syndrome (CRS) and neurological toxicities (ICANS). This manuscript aims to provide a consensus of specialists in the fields of Hematology Oncology and Cellular Therapy to make recommendations on the current scenario of the use of CAR-T cells in patients with ALL.Adriana SeberClaudio Galvão de CastroJuniorLucila N. KerbauyAlexandre V. HirayamaCarmem BonfimJuliana Folloni FernandesMair SouzaRony SchafellSamir NabhanSandra Regina LoggettoBelinda Pinto SimõesVanderson RochaMarcos de LimaRenato L. Guerino-CunhaHenrique BittencourtElsevierarticleCellular therapyCar-T cellsImmunotherapyAdoptive cellular therapyAdvanced cellular therapyAcute lymphoblastic leukemiaDiseases of the blood and blood-forming organsRC633-647.5ENHematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S13-S21 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Cellular therapy Car-T cells Immunotherapy Adoptive cellular therapy Advanced cellular therapy Acute lymphoblastic leukemia Diseases of the blood and blood-forming organs RC633-647.5 |
| spellingShingle |
Cellular therapy Car-T cells Immunotherapy Adoptive cellular therapy Advanced cellular therapy Acute lymphoblastic leukemia Diseases of the blood and blood-forming organs RC633-647.5 Adriana Seber Claudio Galvão de CastroJunior Lucila N. Kerbauy Alexandre V. Hirayama Carmem Bonfim Juliana Folloni Fernandes Mair Souza Rony Schafell Samir Nabhan Sandra Regina Loggetto Belinda Pinto Simões Vanderson Rocha Marcos de Lima Renato L. Guerino-Cunha Henrique Bittencourt Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia |
| description |
Chimeric antigen receptor T (CAR-T) cell therapy is a novel therapeutic modality for acute lymphoblastic leukemia (ALL) with robust outcomes in patients with refractory or relapsed disease. At the same time, CAR-T cell therapy is associated with unique and potentially fatal toxicities, such as cytokine release syndrome (CRS) and neurological toxicities (ICANS). This manuscript aims to provide a consensus of specialists in the fields of Hematology Oncology and Cellular Therapy to make recommendations on the current scenario of the use of CAR-T cells in patients with ALL. |
| format |
article |
| author |
Adriana Seber Claudio Galvão de CastroJunior Lucila N. Kerbauy Alexandre V. Hirayama Carmem Bonfim Juliana Folloni Fernandes Mair Souza Rony Schafell Samir Nabhan Sandra Regina Loggetto Belinda Pinto Simões Vanderson Rocha Marcos de Lima Renato L. Guerino-Cunha Henrique Bittencourt |
| author_facet |
Adriana Seber Claudio Galvão de CastroJunior Lucila N. Kerbauy Alexandre V. Hirayama Carmem Bonfim Juliana Folloni Fernandes Mair Souza Rony Schafell Samir Nabhan Sandra Regina Loggetto Belinda Pinto Simões Vanderson Rocha Marcos de Lima Renato L. Guerino-Cunha Henrique Bittencourt |
| author_sort |
Adriana Seber |
| title |
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia |
| title_short |
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia |
| title_full |
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia |
| title_fullStr |
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia |
| title_full_unstemmed |
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia |
| title_sort |
associação brasileira de hematologia, hemoterapia e terapia celular consensus on genetically modified cells. ii: car-t cell therapy for patients with cd19+ acute lymphoblastic leukemia |
| publisher |
Elsevier |
| publishDate |
2021 |
| url |
https://doaj.org/article/47a011b41a24447fbfbe666a71b1e194 |
| work_keys_str_mv |
AT adrianaseber associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiicartcelltherapyforpatientswithcd19acutelymphoblasticleukemia AT claudiogalvaodecastrojunior associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiicartcelltherapyforpatientswithcd19acutelymphoblasticleukemia AT lucilankerbauy associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiicartcelltherapyforpatientswithcd19acutelymphoblasticleukemia AT alexandrevhirayama associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiicartcelltherapyforpatientswithcd19acutelymphoblasticleukemia AT carmembonfim associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiicartcelltherapyforpatientswithcd19acutelymphoblasticleukemia AT julianafollonifernandes associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiicartcelltherapyforpatientswithcd19acutelymphoblasticleukemia AT mairsouza associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiicartcelltherapyforpatientswithcd19acutelymphoblasticleukemia AT ronyschafell associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiicartcelltherapyforpatientswithcd19acutelymphoblasticleukemia AT samirnabhan associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiicartcelltherapyforpatientswithcd19acutelymphoblasticleukemia AT sandrareginaloggetto associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiicartcelltherapyforpatientswithcd19acutelymphoblasticleukemia AT belindapintosimoes associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiicartcelltherapyforpatientswithcd19acutelymphoblasticleukemia AT vandersonrocha associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiicartcelltherapyforpatientswithcd19acutelymphoblasticleukemia AT marcosdelima associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiicartcelltherapyforpatientswithcd19acutelymphoblasticleukemia AT renatolguerinocunha associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiicartcelltherapyforpatientswithcd19acutelymphoblasticleukemia AT henriquebittencourt associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiicartcelltherapyforpatientswithcd19acutelymphoblasticleukemia |
| _version_ |
1718424970576527360 |